GAUDIUM IVF AND WOMEN HEALTH LIMITED intimated a board meeting on 12 Nov 2026 to consider unaudited standalone and consolidated half-yearly results for the period ended September 2026. No financial figures are disclosed in this intimation.
Gaudium IVF and Women Health Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI regulations.
Gaudium IVF conducted its 11th Annual General Meeting on September 28, 2026, via video conferencing, transacting all businesses specified in the AGM notice.
Gaudium IVF and Women Health Limited has intimated the exchange about sending physical letters to shareholders for accessing the Annual Report for FY 2025-26.
Gaudium IVF and Women Health Limited submitted its Annual Report for the Financial Year 2025-26. The 11th Annual General Meeting is scheduled for September 28, 2026.
Gaudium IVF and Women Health Limited will hold its 11th AGM on September 28, 2026. The meeting will be conducted via Video Conferencing to consider several resolutions.
Gaudium IVF reported Q1 FY27 consolidated revenue of Rs. 1,937.66 Lakhs, up 9.13% YoY, while front-loading expansion costs for new hubs and AI integration.
Gaudium IVF will commence commercial operations at its new South Extension centre on July 16, 2026. This expansion aligns with the company's IPO prospectus objectives.
Gaudium IVF issued a corrigendum to correct typographical errors in consolidated results. The changes relate only to comparative figures for March 31, 2025.
Gaudium IVF reported strong FY26 performance with consolidated revenue at ₹10,435.70 Lakhs and PAT of ₹2,448.85 Lakhs, driven by its recent IPO and AI-led clinical excellence.
Gaudium IVF reported consolidated annual profit of ₹24.49 Crore on revenue of ₹104.36 Crore. The Board approved these audited results for the period ending March 2026.
NCLT New Delhi Bench rejected an insolvency petition filed against Gaudium IVF by Ramaa Capital. This decision removes immediate legal risk from the operational creditor's IBC claim.
Gaudium IVF scheduled a board meeting for May 28, 2026, to approve annual audited financial results. The trading window remains closed until 48 hours after declaration.